The company is developing multiplexed and reverse-phase array versions of its protein phosphorylation-detection technology.
The company aims to use the funding to further optimize the technology and support an ongoing early-access program with beta testers.
The company said the library will be made freely available to academic and non-profit investigators through the DECIPHER Project.
The company aims to launch the qPCR-based test in sub-Saharan Africa.
The products will initially be commercialized for research applications, but the firm hopes to move into diagnostics down the road.
The two-year grant is worth $350,000 in its first year.
The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.
The grant project is part of the company's ongoing effort to expand into pre-designed research tests for disease biomarkers and point-of-care diagnostics.
The company is using a $3 million, three-year grant to clinically validate the test, which it hopes will be the first of its kind approved by the FDA.
The company has previously published data showing the miRNA expression in plasma could identify patients with mild cognitive impairment with 96 percent accuracy.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.